Ең жақсы аналық бездің рагінің дәрігерлері - ЖОҒ-103 дәрігерлер

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

One of the best cancer specialists in Europe, educator, and cancer researcher, President of the Central European Cooperative Oncology Group (CECOG).
Has published over 600 scientific papers on cancer treatment.

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

Education/Residency:

• Completed residency in general oncology and radiotherapy (radiation therapy) at Sheba Hospital, Tel Hashomer.
• During her work, she gained extensive experience in treating tumors of the female reproductive system and is currently a coordinator for the treatment of patients suffering from these diseases.
• Fellowship - Anderson Cancer Center, Houston, Texas - 2012-2014

Dr. Tatyana Rabin's research interests include:

Methods of destruction of malignant neoplasms by heating with the help of ultrasonic waves, research into the use of brachytherapy in the treatment of oncogynecological diseases,

study of the mechanisms of response at the molecular level of prostate tumor cells to radiotherapy;

clinical studies of oncomammology, oncopulmonology, ocular lymphoma.

Dr. Rabin is investigating the molecular mechanisms by which prostate cancer cells respond to radiation therapy. This research is being conducted in collaboration with the Weizmann Institute of Science.

In addition, Dr. Rabin has been involved in clinical research in the areas of breast cancer, lung cancer, and ocular lymphoma.

Dr. Rabin is currently coordinating a new and unique study at Sheba Hospital that is investigating a method of treating cancerous tumors using MRI-guided ultrasound waves. This method involves raising the tumor's temperature to a certain level and then destroying it.

Awards:

Dr. Tatyana Rabin was recognized as the best hospital employee for 2007.

Experience and participation in scientific research:

• Scientific research in the field of gynecological oncology
• Scientific research in the field of lung tumors
• Application of brachytherapy in oncogynecology
• SBRT techniques in the treatment of tumors of the respiratory system
• Study of molecular mechanisms of prostate tumor cell response to radiation therapy. This study was organized in collaboration with the laboratory of the H. Weizmann Institute.
• In addition, Dr. Rabin has been involved in clinical research in the areas of breast cancer, lung cancer, and ocular lymphoma.

Membership in medical societies :

• Israel Society of Oncology and Clinical Radiotherapy (ISCORT) American Society of Radiology and Oncology (ASTRO)
• Israel Association of Palliative Medicine

Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

Professor Dan Grisaro is a leading Israeli specialist in gynecological cancer diagnosis and treatment, specializing in ovarian cancer, uterine cancer, and cervical cancer. He has senior physician, head of department and lecturer experience at various medical centers and universities. He has held 39 presentations and is the author of 83 published scientific articles, and is a member of various professional societies.

Доктор Виола Фокс BKZ Золингендегі Гематология, Онкология және Паллиативтік медицина клиникасының бас дәрігері болып табылады. Бұл клиника сертификатталған пәнаралық қатерлі ісік орталығы. Доктор Фокс ісік ауруларын дәрі-дәрмекпен емдеуде Германия мен Еуропадағы жетекші сарапшы болып табылады. Ол осы салада 15 жылдан астам тәжірибесі бар.

Ол Германияның Онкология және Гематология-онкология Қоғамының (GDHO), Германия Дәрігерлер қауымдастығының және Американдық Қатерлі Ісік Зерттеу Қауымдастығының мүшесі болып табылады. Доктор Фокс молекулалық биология бойынша да зерттеулер жүргізеді. Оның жұмысы қатерлі ісікті емдеу мен молекулалық диагностика саласының алға жылжыуына қолдау көрсетеді.

Оның негізгі маманданған салалары химиотерапия, иммунотерапия, мақсатты терапия және радиациялық терапия болып табылады. Доктор Фокс инновациялық әдістері мен пациенттерге қамқорлық жасаудағы жоғары құлшынысымен танымал. Оның күш-жігері жоғары қалпына келу көрсеткіштерімен және әріптестерінің мойындауымен ерекшеленеді.

Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.

She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.

Дәрігер Северин Иборра - Штадтичес Клиникам Золингендегі Гинекология және Акушерлік Бөлімінің Бас Дәрігері. Оның міндеттеріне акушерлік, босану залы, жаңа туған нәрестелер бөлімі және гинекология кіреді. Бөлімде сонымен қатар, доктор Мануэла Зайферт басқаратын, Золингендегі Бергиш Сүт Безі Орталығындағы Сеноология/Сүт Безі Клиникасы да бар.

Дәрігер Северин Иборра Франциядан шыққан. Ол медициналық оқуын Лион Университетінде бастаған және кейін Фрайбургтегі Альберт-Людвигс Университетіне ауысып, 2007 жылы медициналық лицензиясын алған. Ол молекулярлық онкология бойынша эксперименттік зерттеулер үшін 2008 жылы докторлық дәреже алды. Тамыз 2008 ж. - қараша 2013 ж. аралығында доктор Иборра Фрайбургтегі Университет Әйелдер Клиникасында резидент ретінде жұмыс істеді. Гинекология және акушерлік бойынша мамандық емтихандарын тапсырғаннан кейін, ол сол клиникада маман ретінде мансапын жалғастырды. 2015 жылдың қарашасында ол Ахендегі РВТХ Университеті Ауруханасына аға дәрігер ретінде ауысты.

Профессор доктор Э. Стикелер жетекшілігіндегі Гинекология және Акушерлік Клиникасында, доктор Иборра 2017 жылдан 2019 жылға дейін акушерлік бөлімді басқарды. 2017 жылдың желтоқсанынан бастап ол бөлімде білім беру ұйымдастыруына жауапты болды, ал 2019 жылдың қазан айында, ол Золингенге ауыспастан бұрын, Клиниканың Басқарушы Аға Дәрігері және Кадрлық Аға Дәрігері болды.

Көптеген басылымдар мен ірі гинекологиялық конференцияларда баяндамалар жасаған ғылыми жұмысынан бөлек, доктор Иборра медициналық мамандықтарын тереңдетті. Ол Гинекологиялық Онкология Жұмыс Тобынан онкологиялық диагностика және терапия бойынша сертификаттар алды, сондай-ақ, Бұлшықет Цервикал Патологиясы және Кольпоскопия (АГЦПК), Урогинекология және Жамбас Реконструкциялық Хирургиясы (АГУП) және Гинекологтар Кәсіби Қауымдастығында (БВФ) қосымша біліктіліктер алды.

2019 жылы доктор Иборра "Гинекологиялық Онкология" және "Арнайы Акушерлік және Перинаталдық Медицина" бойынша әрі қарайғы мамандануын сәтті аяқтады. Ол өз саласында жетекші неміс медициналық қоғамдарының, соның ішінде Неміс Гинекология және Акушерлік Қоғамының, Цервикал Патология және Кольпоскопия Жұмыс Тобының, сондай-ақ Неміс Пренаталдық және Босану Медицина Қоғамының белсенді мүшесі.

Біздің Гинекология Бөлімінде Ұсынылған Емдеу Түрлері

• Гистероскопия және Кеңейту мен Кюретаж (Д&К) диагностикалық және емдік мақсаттарда.
• Жұмыртқа бездеріндегі ақаулы немесе симптомдық табысты алып тастау, қоқысын сақтау.
• Ооофорэктомия (жұмыртқа бездерін алып тастау) ауытқулар кезінде немесе көрсетілетін алдын алу ретінде.
• Миомэктомия (жатырдағы миомаларды алып тастау) жатырды сақтау.
• Миомаларды консервативті емдеу: радиология мамандары жүргізетін дәрігерлік емдеу немесе эмболизация.
• Гистерэктомия мойынды алып тастау немесе алмай.
• Түсініксіз табыстарды диагостика және тазартыу жатыр мойны, қынап және сыртқы жыныс мүшелерінде.
• Дисплазияны емдеу.
• Эндометриозды басқару.
• Қатерлі ісік емдеу сыртқы жыныс мүшелері, қынап, жатыр мойны, жатыр және жұмыртқа бездерінің қатерлі ісіктеріне арналған.
• Несеп ұстамау және/немесе жамбас органдарының пролапсы үшін емдеу.

Мүмкін болған кезде, біз барлық процедураларды лапароскопия немесе Да Винчи робот жүйесін қолданып аз инвазивті емдер ретінде ұсынамыз.

Dr. Hamdullah Sozen is a gynecologic oncologist with expertise in ovarian, endometrial, and cervical cancers. He is known for his skills in gynecological endoscopic surgery. Dr. Sozen uses minimally invasive techniques that help patients recover faster and improve outcomes.

He is an expert in colposcopy and cervical pathology. He has advanced training in both diagnostic and interventional procedures. Dr. Sozen completed his medical and oncology training at leading Turkish institutions, including Akdeniz University, Zeynep Kamil, and Istanbul Medical Faculty.

He is an active member of international associations such as ESGO and MEMAGO. Dr. Sozen has contributed to women’s cancer care through his clinical work, research, and teaching.

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.​

Education and Training:

Graduated in Medicine and Surgery from the University of Navarra (1985).​

Completed residency in Oncology in 1987.​

Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).​

Professional Experience:

Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).​

Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).​

Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).

Head of the Oncology Department at Hospital General de Villalba (2014–2019).​

Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.​

Certifications and Training:

Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.​

Research and Publications:

Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

Oncogynecologist. Specialist in minimally invasive surgeries